Boxer Capital Management LLC Takes Position in Milestone Pharmaceuticals Inc. (NASDAQ:MIST)

Boxer Capital Management LLC purchased a new stake in shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 309,007 shares of the company's stock, valued at approximately $729,000. Boxer Capital Management LLC owned approximately 0.58% of Milestone Pharmaceuticals at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Jones Financial Companies Lllp grew its position in shares of Milestone Pharmaceuticals by 1,000.0% in the fourth quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company's stock valued at $26,000 after purchasing an additional 10,000 shares in the last quarter. National Bank of Canada FI increased its position in shares of Milestone Pharmaceuticals by 163.4% during the fourth quarter. National Bank of Canada FI now owns 18,700 shares of the company's stock valued at $44,000 after buying an additional 11,600 shares during the period. XTX Topco Ltd purchased a new stake in shares of Milestone Pharmaceuticals in the fourth quarter worth about $80,000. Northern Trust Corp grew its stake in Milestone Pharmaceuticals by 112.6% during the fourth quarter. Northern Trust Corp now owns 58,108 shares of the company's stock valued at $137,000 after acquiring an additional 30,772 shares in the last quarter. Finally, Virtu Financial LLC purchased a new position in Milestone Pharmaceuticals during the fourth quarter valued at approximately $170,000. 86.18% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. TD Cowen lowered shares of Milestone Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, April 1st. HC Wainwright reaffirmed a "buy" rating and issued a $25.00 price target on shares of Milestone Pharmaceuticals in a report on Friday, March 28th. TD Securities cut shares of Milestone Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Tuesday, April 1st. Finally, Cowen lowered shares of Milestone Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Tuesday, April 1st. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $17.00.

Milestone Pharmaceuticals Trading Down 0.8 %

Milestone Pharmaceuticals stock traded down $0.01 during mid-day trading on Friday, hitting $1.31. The company's stock had a trading volume of 1,888,567 shares, compared to its average volume of 854,823. The business has a 50 day moving average price of $1.38 and a 200-day moving average price of $1.73. Milestone Pharmaceuticals Inc. has a 12 month low of $0.63 and a 12 month high of $2.75. The stock has a market cap of $69.89 million, a price-to-earnings ratio of -1.62 and a beta of 1.38. The company has a debt-to-equity ratio of 2.18, a current ratio of 15.40 and a quick ratio of 15.40.

Milestone Pharmaceuticals Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.